Lisdeksamfetamin

Lisdeksamfetamin
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	< 1 h
Identifikatori
CAS broj	608137-32-2
ATC kod	None
PubChem	CID 11597698
DrugBank	DB01255
ChemSpider	9772458
ChEMBL	CHEMBL1201222
Hemijski podaci
Formula	C15H25N3O
Molarna masa	263,378
	SMILES C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN; ;
	InChI InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1 ; Key:VOBHXZCDAVEXEY-JSGCOSHPSA-N ;

Lisdeksamfetamin je organsko jedinjenje, koje sadrži 15 atoma ugljenika i ima molekulsku masu od 263,378 Da.^[1]^[2]^[3]^[4]^[5]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	3
Broj rotacionih veza	8
Particioni koeficijent^[6] (ALogP)	1,1
Rastvorljivost^[7] (logS, log(mol/L))	-3,9
Polarna površina^[8] (PSA, Å²)	81,1

Reference

^ Jasinski, D. R.; Krishnan, S. (2008). „Human pharmacology of intravenous lisdexamfetamine dimesylate: Abuse liability in adult stimulant abusers”. J Psychopharmacol. 23 (4): 410—418. PMID 18635707. doi:10.1177/0269881108093841.
^ Madaan, V. (мај 2008). „Lisdexamfetamine dimesylate for childhood ADHD”. Drugs of Today (Barcelona, Spain : 1998). 44 (5): 319—24. PMID 18548134. doi:10.1358/dot.2008.44.5.1215724.
^ Krishnan, S.; Moncrief, S. (јануар 2007). „An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes”. Drug Metab Dispos. 35 (1): 180—4. PMID 17035599. doi:10.1124/dmd.106.011973.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Lisdexamfetamine

[1] Jasinski, D. R.; Krishnan, S. (2008). „Human pharmacology of intravenous lisdexamfetamine dimesylate: Abuse liability in adult stimulant abusers”. J Psychopharmacol. 23 (4): 410—418. PMID 18635707. doi:10.1177/0269881108093841.

[2] Madaan, V. (мај 2008). „Lisdexamfetamine dimesylate for childhood ADHD”. Drugs of Today (Barcelona, Spain : 1998). 44 (5): 319—24. PMID 18548134. doi:10.1358/dot.2008.44.5.1215724.

[3] Krishnan, S.; Moncrief, S. (јануар 2007). „An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes”. Drug Metab Dispos. 35 (1): 180—4. PMID 17035599. doi:10.1124/dmd.106.011973.

[4] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[5] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[6] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[7] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[8] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]